IDXX IDEXX LABORATORIES INC /DE
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 874716 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.9%
TTM net income YoY15.1%
TTM EPS YoY17.7%
Revenue 3-yr CAGR9.1%
Net income 3-yr CAGR12.8%
Margins
Gross margin62.7%
Operating margin32.3%
Net margin25.4%
FCF margin28.0%
EBITDA margin35.7%
Returns
ROE68.9%
ROA33.3%
ROIC (approx.)61.4%
Asset turnover1.31x
Leverage & solvency
Liabilities / assets49.6%
Debt / equity0.20x
Current ratio1.19x
Interest coverage43.54x
Cash quality & payout
Operating cash flow / net income1.20x
Accruals ratio-6.7%
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $4.30B | $3.90B |
| Cost of revenue | $1.64B | $1.52B |
| Gross profit | $2.66B | $2.38B |
| R&D expense | $251.21M | $219.79M |
| SG&A expense | $404.79M | $442.29M |
| Operating income | $1.36B | $1.13B |
| Interest expense | $38.85M | $31.20M |
| Pretax income | $1.32B | $1.11B |
| Income tax | $264.73M | $221.96M |
| Net income | $1.06B | $887.87M |
| EBITDA | $1.51B | $1.26B |
| EPS (basic) | 13.17 | 10.77 |
| EPS (diluted) | 13.08 | 10.67 |
| Weighted avg. shares (diluted) | 81.03M | 83.25M |
| Banking | ||
| Provision for credit losses | $8.43M | $6.87M |
| Balance sheet | ||
| Cash & equivalents | $180.07M | $288.27M |
| Receivables | $552.38M | $473.57M |
| Inventory | $377.76M | $381.88M |
| Current assets | $1.41B | $1.40B |
| PP&E, net | $747.38M | $713.12M |
| Goodwill | $414.00M | $405.10M |
| Intangibles | $109.84M | $111.68M |
| Total assets | $3.35B | $3.29B |
| Current liabilities | $1.15B | $1.07B |
| Short-term debt | $75.00M | $167.79M |
| Long-term debt | $374.84M | $449.79M |
| Total debt | $449.84M | $617.57M |
| Total liabilities | $1.75B | $1.70B |
| Shareholders' equity | $1.61B | $1.60B |
| Net debt | $269.77M | $329.31M |
| Shares outstanding | 79.71M | 81.60M |
| Cash flow statement | ||
| Operating cash flow | $1.18B | $929.00M |
| Capital expenditure | $124.68M | $120.92M |
| Free cash flow | $1.06B | $808.08M |
| Investing cash flow | -$136.24M | -$207.06M |
| Financing cash flow | -$1.16B | -$878.07M |
| Depreciation & amortization | $145.18M | $129.94M |
| Stock-based compensation | $60.01M | $60.30M |
| Share buybacks | $1.22B | $837.03M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.